Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Bei Sun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0004-2256-4090; OpenAlex author ID A5100704104. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
32
Papers, trials and grants by year

2019: 2 papers · 2020: none · 2021: 3 papers · 2022: none · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 8

  1. Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Format… Last author DOI 10.1158/0008-5472.can-25-2854↗
  2. Tumor Cell Derived Lnc-FSD2-31:1 Contributes to Cancer-Associated Fibroblasts Activation in Pancreatic Ductal Adenocarcinoma Progression through Extracellular … Last author DOI 10.1002/advs.202203324↗
  3. circEIF3I facilitates the recruitment of SMAD3 to early endosomes to promote TGF-β signalling pathway-mediated activation of MMPs in pancreatic cancer. Last author DOI 10.1186/s12943-023-01847-2↗
  4. Invadopodia: A potential target for pancreatic cancer therapy. Co-author DOI 10.1016/j.critrevonc.2021.103236↗
  5. Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer. Last author DOI 10.3389/fcell.2021.655152↗
  6. Beneficial Diets and Pancreatic Cancer: Molecular Mechanisms and Clinical Practice. Last author DOI 10.3389/fonc.2021.630972↗
  7. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway. Co-author DOI 10.1186/s13045-019-0837-z↗
  8. [Research advances on the value of preoperative systemic inflammatory response index in predicting the prognosis of patients with resectable pancreatic cancer]. Last author DOI 10.3760/cma.j.issn.0529-5815.2019.11.013↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guanqun Li · 5 shared papers, 2021–2026 · strength 0.77
  2. Yongwei Wang · 5 shared papers, 2019–2026 · strength 0.72
  3. Jisheng Hu · 4 shared papers, 2021–2026 · strength 0.64
  4. Rui Kong · 4 shared papers, 2019–2026 · strength 0.60
  5. Xinglong Geng · 4 shared papers, 2021–2023 · strength 0.54
  6. Wenbo Yang · 4 shared papers, 2021–2023 · strength 0.54
  7. Hongze Chen · 4 shared papers, 2021–2023 · strength 0.54
  8. Chundong Cheng · 3 shared papers, 2021–2023 · strength 0.41
  9. Zhongjie Zhao · 3 shared papers, 2021–2023 · strength 0.41
  10. Yan Luo · 2 shared papers, 2023–2026 · strength 0.38
  11. Gang Wang · 2 shared papers, 2023–2026 · strength 0.38
  12. Le Li · 2 shared papers, 2021–2026 · strength 0.36
  13. Le Li · 2 shared papers, 2023 · strength 0.28
  14. Yangyang Zhang · 2 shared papers, 2023 · strength 0.28
  15. Danxi Liu · 2 shared papers, 2023 · strength 0.28
  16. Tao Zhang · 2 shared papers, 2021–2023 · strength 0.27
  17. Xuewei Bai · 2 shared papers, 2019–2023 · strength 0.21
  18. Le Li · 2 shared papers, 2019–2021 · strength 0.20
  19. Hua Chen · 1 shared paper, 2019 · strength 0.16
  20. C P Jia · 1 shared paper, 2019 · strength 0.16
  21. Yan Luo · 1 shared paper, 2021 · strength 0.15
  22. Zengfu Song · 1 shared paper, 2023 · strength 0.14
  23. Shangha Pan · 1 shared paper, 2023 · strength 0.14
  24. Yang Zhang · 1 shared paper, 2021 · strength 0.13
  25. Qiushi Lin · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.